Hemostemix (TSXV:HEM; OTCQB:HMTXF) has announced that it has secured an arm’s length perpetual, royalty-free global license to CytoImmune’s BioReactor stem cell technologies. Subject to the TSXV Exchange acceptance, Hemostemix will pay CytoImmune $5,000,000 (twenty million shares) for the license.
Hemostemix underscores that securing this license will provide the company with an economic and competitive advantage enabling it to scale its proprietary ACP-01—the gold standard for personalized regenerative medicine. Moreover, the license will protect Hemostemix’s autologous stem cell market, and create a cost-effective allogenic stem cell expansion strategy.
In a statement, Thomas Smeenk, CEO of Hemostemix, said, “We invite investors to recognize the long-term impact of this milestone as we continue to expand Hemostemix’s leadership in the global stem cell market.”
